IVD SYSTEMS & AUTOMATED CLINICAL DIAGNOSTIC ANALYSERS
banner35.jpg

MicroELISA

All Reagents You Need, Available in One Click

Application Product Information & Purchase Order

Method & Line Sample & Target Product Package Info Product Package Info
MicroELISA Serum EIAgen OV-Marker CA 125 Kit Tests per Package: 96
EIAgen EIAgen OV-Marker CA 125 Kit is a direct solid phase enzyme immunoassay for the quantitative measurement of Cancer Antigen 125 (CA-125) in human serum. Code: LI4035F1 Package: 1 Microplate
image not exist
  • Stock:
  • Available
    *Usually shipping within 5 business days
  • Min Order:
  • 5 Kits
  • Shipping:
  • Not Included

For Quantity Orders: Request a Quote

  • Stock:
  • Available
    *Usually shipping within 5 business days
  • Min Order:
  • 5 Kits
  • Shipping:
  • Not Included

For Quantity Orders: Request a Quote

Please pay attention to the revision of the document that must be the same as the revision reported in the box label.
In case of discrepancy please contact our Customer Care e-mail: info@adaltis.net.

* Other document related to the product available at Documentation Centre and it is accessible for Adaltis distributors/partners after registration only.

EIAgen OV-Marker CA 125 Kit is a direct solid phase enzyme immunoassay for the quantitative measurement of Cancer Antigen 125 (CA-125) in human serum.

Cancer Antigen 125 (CA-125) is a glycoprotein that occurs in blood as high molecular weight entity (MBrB > 200,000). High concentrations of this antigen are associated with ovarian cancer and a range of benign and malignant diseases. Although the specificity and sensitivity of CA-125 assays are somewhat limited, especially in early diagnosis of ovarian cancer, the assay has found widespread use in the differential diagnosis of adnexal masses, in monitoring disease progression and response to therapy in ovarian cancer, and in the early detection of recurrence after surgery or chemotherapy for ovarian cancer. Published literature has shown that elevated serum CA-125 levels can be observed in patients with serious endometroid, clear cell and undifferentiated ovarian carcinoma. The serum CA-125 is elevated in 1% of normal healthy women, 3% of normal healthy women with benign ovarian diseases, and 6% of patients with non-neoplastic conditions (including but not limited to first trimester pregnancy, menstruation, endometriosis uterine fibrosis, acute salphingitis, hepatic diseases and inflammation of peritoneum or pericardium).

In this method, CA-125 calibrator, patient specimen or control is first added to a streptavidin coated well. Biotinylated monoclonal and enzyme labeled antibodies (directed against distinct and different epitopes of CA-125) are added and the reactants mixed. Reaction between the various CA-125 antibodies and native CA-125 forms a sandwich complex that binds with the streptavidin coated to the well.

After the completion of the required incubation period, the enzyme-CA-125 antibody bound conjugate is separated from the unbound enzyme-CA-125 conjugate by aspiration or decantation. The activity of the enzyme present on the surface of the well is quantitated by reaction with a suitable substrate to produce color.

The employment of several serum references of known Cancer Antigen 125 (CA-125) levels permits the construction of a dose response curve of activity and con­centration. From comparison to the dose response curve, an unknown specimen's activity can be correlated with CA-125 concentration.

Immunoenzymometric assay:

The essential reagents required for an immunoenzymometric assay include high affinity and specificity antibodies (enzyme and immobilized), with different and distinct epitope recognition, in excess, and native antigen. In this procedure, the immobilization takes place during the assay at the surface of a microplate well through the interaction of streptavidin coated on the well and exogenously added biotinylated monoclonal anti-CA-125 antibody.

Upon mixing monoclonal biotinylated antibody, the enzyme-labeled antibody and a serum containing the native antigen, reaction results between the native antigen and the antibodies, without competition or steric hindrance, to form a soluble sandwich complex.

Simultaneously, the complex is deposited to the well through the high affinity reaction of streptavidin and biotinylated antibody.  

After equilibrium is attained, the antibody‑bound fraction is separated from unbound antigen by decantation or aspiration. The enzyme activity in the antibody‑bound fraction is directly proportional to the native antigen concentration. By utilizing several different serum references of known antigen values, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.

The kit contains reagents for 96 tests (code LI4035F1).

Bring reagents to room temperature before use.

Microplate

Calibrators

HRP Conjugate

Substrate TMB

Stop Solution

Wash Buffer Conc. 50X

Adhesive Films

12x8 wells

6x1 mL/vials

1x13 mL/vial

1x16 mL/vial

1x15 mL/vial

1x20 mL/vial

2

Number of tests

96

Code

LI4035F1

Need assistance to make an order? Contact Sales & Orders Centre order@adaltis.net.
For Application Support application@adaltis.net